1
|
Gediya P, Vyas VK, Carafa V, Sitwala N, Della Torre L, Poziello A, Kurohara T, Suzuki T, Sanna V, Raguraman V, Suthindhiran K, Ghosh D, Bhatia D, Altucci L, Ghate MD. Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors. Bioorg Chem 2021; 110:104801. [PMID: 33756235 DOI: 10.1016/j.bioorg.2021.104801] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2021] [Revised: 02/27/2021] [Accepted: 03/01/2021] [Indexed: 10/22/2022]
Abstract
The discovery and development of isoform-selective histone deacetylase (HDAC) inhibitor is a challenging task because of the sequence homology among HDAC enzymes. In the present work, novel tetrahydro benzo[b]thiophene-3-carbonitrile based benzamides were designed, synthesized, and evaluated as HDAC inhibitors. Pharmacophore modeling was our main design strategy, and two novel series of tetrahydro benzo[b]thiophene-3-carbonitrile derivatives with piperidine linker (series 1) and piperazine linker (series 2) were identified as HDAC inhibitors. Among all the synthesised compounds, 9h with 4-(aminomethyl) piperidine linker and 14n with piperazine linker demonstrated good activity against human HDAC1 and HDAC6, respectively. Both the compounds also exhibited good antiproliferative activity against several human cancer cell lines. Both these compounds (9h and 14n) also induced cell cycle arrest and apoptosis in U937 and MDA-MB-231 cancer cells. Overall, for the first time, this research discovered potent isoform-selective HDAC inhibitors using cyclic linker instead of the aliphatic chain and aromatic ring system, which were reported in known HDAC inhibitors.
Collapse
Affiliation(s)
- Piyush Gediya
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India
| | - Vivek K Vyas
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India
| | - Vincenzo Carafa
- Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Via L. De Crecchio 7, 80138 Naples, Italy
| | - Nikum Sitwala
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India
| | - Laura Della Torre
- Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Via L. De Crecchio 7, 80138 Naples, Italy
| | - Angelita Poziello
- Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Via L. De Crecchio 7, 80138 Naples, Italy
| | - Takashi Kurohara
- The Institute of Scientific and Industrial Research (ISIR), Osaka University, Mihogaoka, Ibarakishi, Osaka 567-0047, Japan
| | - Takayoshi Suzuki
- The Institute of Scientific and Industrial Research (ISIR), Osaka University, Mihogaoka, Ibarakishi, Osaka 567-0047, Japan
| | - Vinod Sanna
- Piramal Pharma Solution, Plot-18 Pharmaceutical Special Economic Zone, Sarkhej-Bawla, NH-8A, Ahmedabad, Gujarat 382213, India
| | - Varalakshmi Raguraman
- School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamilnadu, India
| | - K Suthindhiran
- School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamilnadu, India
| | - Debarpan Ghosh
- Department of Biological Engineering, Indian Institute of Technology, Gandhinagar 382355, Gujarat, India
| | - Dhiraj Bhatia
- Department of Biological Engineering, Indian Institute of Technology, Gandhinagar 382355, Gujarat, India
| | - Lucia Altucci
- Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Via L. De Crecchio 7, 80138 Naples, Italy.
| | - Manjunath D Ghate
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad 382481, Gujarat, India.
| |
Collapse
|
2
|
Poziello A, Nebbioso A, Stunnenberg HG, Martens JHA, Carafa V, Altucci L. Recent insights into Histone Acetyltransferase-1: biological function and involvement in pathogenesis. Epigenetics 2020; 16:838-850. [PMID: 33016232 DOI: 10.1080/15592294.2020.1827723] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Acetylation of histone and non-histone proteins is a post-translational modification mostly associated with activation of gene transcription. The first histone acetyltransferase (HAT) identified as modifying newly synthesized histone H4 in yeast was a type B HAT named HAT1. Although it was the first HAT to be discovered, HAT1 remains one of the most poorly studied enzymes in its class. In addition to its well-established role in the cytoplasm, recent findings have revealed new and intriguing aspects of the function of HAT1 in the nucleus. Several studies have described its involvement in regulating different pathways associated with a wide range of diseases, including cancer. This review focuses on our current understanding of HAT1, highlighting its importance in regulating chromatin replication and gene expression. This previously unknown role for HAT1 opens up novel scenarios in which further studies will be required to better understand its function.
Collapse
Affiliation(s)
- Angelita Poziello
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.,Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, GA, The Netherlands
| | - Angela Nebbioso
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Hendrik G Stunnenberg
- Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, GA, The Netherlands.,Princess Maxima Center for Pediatric Oncology, Utrecht, CS, The Netherlands
| | - Joost H A Martens
- Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, GA, The Netherlands
| | - Vincenzo Carafa
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Lucia Altucci
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| |
Collapse
|
3
|
Carafa V, Poziello A, Della Torre L, Giovannelli P, Di Donato M, Safadeh E, Yu Z, Baldi A, Castoria G, Tomaselli D, Mai A, Rotili D, Nebbioso A, Altucci L. Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. Int J Mol Sci 2019; 20:ijms20225654. [PMID: 31726691 PMCID: PMC6888689 DOI: 10.3390/ijms20225654] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Revised: 11/05/2019] [Accepted: 11/08/2019] [Indexed: 01/13/2023] Open
Abstract
Sirtuins, a family of nicotinamide adenine dinucleotide (NAD+)-dependent lysine deacetylases, are promising targets for anticancer treatment. Recently, we characterized a novel pan-sirtuin (SIRT) inhibitor, MC2494, displaying antiproliferative effects and able to induce death pathways in several human cancer cell lines and decrease tumor growth in vivo. Based on the chemical scaffold of MC2494, and by applying a structure–activity relationship approach, we developed a small library of derivative compounds and extensively analyzed their enzymatic action at cellular level as well as their ability to induce cell death. We also investigated the effect of MC2494 on regulation of cell cycle progression in different cancer cell lines. Our investigations indicated that chemical substitutions applied to MC2494 scaffold did not confer higher efficacy in terms of biological activity and SIRT1 inhibition, but carbethoxy-containing derivatives showed higher SIRT2 specificity. The carbethoxy derivative of MC2494 and its 2-methyl analog displayed the strongest enzymatic activity. Applied chemical modifications improved the enzymatic selectivity of these SIRT inhibitors. Additionally, the observed activity of MC2494 via cell cycle and apoptotic regulation and inhibition of cell migration supports the potential role of SIRTs as targets in tumorigenesis and makes SIRT-targeting molecules good candidates for novel pharmacological approaches in personalized medicine.
Collapse
Affiliation(s)
- Vincenzo Carafa
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
| | - Angelita Poziello
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
| | - Laura Della Torre
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
| | - Pia Giovannelli
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
| | - Marzia Di Donato
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
| | - Elham Safadeh
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
| | - Zhijun Yu
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
| | - Alfonso Baldi
- Dipartimento di Scienze e Tecnologie Ambientali Biologiche e Farmaceutiche Università degli Studi della Campania “Luigi Vanvitelli”, 81100 Caserta, Italy;
| | - Gabriella Castoria
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
| | - Daniela Tomaselli
- Dipartimento di Chimica e Tecnologie del Farmaco “Sapienza” Università di Roma, 00185 Roma, Italy;
| | - Antonello Mai
- Dipartimento di Chimica e Tecnologie del Farmaco “Sapienza” Università di Roma, 00185 Roma, Italy;
- Correspondence: (A.M.); (D.R.); (A.N.); (L.A.); Tel.: +39-0649-913-392 (A.M.); +39-0649-913-891 (D.R.); +39-0815-665-682 (A.N.); +39-0815-667-569 (L.A.); Fax: +39-064-9693-268 (A.M. & D.R.); +39-081-450-169 (A.N. & L.A.)
| | - Dante Rotili
- Dipartimento di Chimica e Tecnologie del Farmaco “Sapienza” Università di Roma, 00185 Roma, Italy;
- Correspondence: (A.M.); (D.R.); (A.N.); (L.A.); Tel.: +39-0649-913-392 (A.M.); +39-0649-913-891 (D.R.); +39-0815-665-682 (A.N.); +39-0815-667-569 (L.A.); Fax: +39-064-9693-268 (A.M. & D.R.); +39-081-450-169 (A.N. & L.A.)
| | - Angela Nebbioso
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
- Correspondence: (A.M.); (D.R.); (A.N.); (L.A.); Tel.: +39-0649-913-392 (A.M.); +39-0649-913-891 (D.R.); +39-0815-665-682 (A.N.); +39-0815-667-569 (L.A.); Fax: +39-064-9693-268 (A.M. & D.R.); +39-081-450-169 (A.N. & L.A.)
| | - Lucia Altucci
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, 80138 Napoli, Italy; (V.C.); (A.P.); (L.D.T.); (P.G.); (M.D.D.); (E.S.); (Z.Y.); (G.C.)
- Correspondence: (A.M.); (D.R.); (A.N.); (L.A.); Tel.: +39-0649-913-392 (A.M.); +39-0649-913-891 (D.R.); +39-0815-665-682 (A.N.); +39-0815-667-569 (L.A.); Fax: +39-064-9693-268 (A.M. & D.R.); +39-081-450-169 (A.N. & L.A.)
| |
Collapse
|
4
|
Andreotti G, Cabeza de Vaca I, Poziello A, Monti MC, Guallar V, Cubellis MV. Conformational response to ligand binding in phosphomannomutase2: insights into inborn glycosylation disorder. J Biol Chem 2014; 289:34900-10. [PMID: 25324542 PMCID: PMC4263888 DOI: 10.1074/jbc.m114.586362] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The most common glycosylation disorder is caused by mutations in the gene encoding phosphomannomutase2, producing a disease still without a cure. Phosphomannomutase2, a homodimer in which each chain is composed of two domains, requires a bisphosphate sugar (either mannose or glucose) as activator, opening a possible drug design path for therapeutic purposes. The crystal structure of human phosphomannomutase2, however, lacks bound substrate and a key active site loop. To speed up drug discovery, we present here the first structural model of a bisphosphate substrate bound to human phosphomannomutase2. Taking advantage of recent developments in all-atom simulation techniques in combination with limited and site-directed proteolysis, we demonstrated that α-glucose 1,6-bisphosphate can adopt two low energy orientations as required for catalysis. Upon ligand binding, the two domains come close, making the protein more compact, in analogy to the enzyme in the crystals from Leishmania mexicana. Moreover, proteolysis was also carried out on two common mutants, R141H and F119L. It was an unexpected finding that the mutant most frequently found in patients, R141H, although inactive, does bind α-glucose 1,6-bisphosphate and changes conformation.
Collapse
Affiliation(s)
- Giuseppina Andreotti
- From the Istituto di Chimica Biomolecolare-Consiglio Nazionale Delle Ricerche, 80078 Pozzuoli, Italy
| | - Israel Cabeza de Vaca
- Joint Barcelona Supercomputing Center-Center for Genomic Regulation-Institute for Research in Biomedicine Research Program in Computational Biology, Barcelona Supercomputing Center, c/Jordi Girona 29, 08034 Barcelona, Spain
| | - Angelita Poziello
- From the Istituto di Chimica Biomolecolare-Consiglio Nazionale Delle Ricerche, 80078 Pozzuoli, Italy, Dipartimento di Biologia, Università Federico II, 80126 Naples, Italy
| | - Maria Chiara Monti
- Dipartimento di Farmacia, Università degli Studi di Salerno, 84084 Fisciano, Italy
| | - Victor Guallar
- Joint Barcelona Supercomputing Center-Center for Genomic Regulation-Institute for Research in Biomedicine Research Program in Computational Biology, Barcelona Supercomputing Center, c/Jordi Girona 29, 08034 Barcelona, Spain, Institució Catalana de Recerca i Estudis Avançats, Passeig Lluís Companys 23, 08010 Barcelona, Spain, and
| | | |
Collapse
|
5
|
Avagliano G, Piccoli S, Grisolia V, Poziello A, Petagna C, Battisti S, Sansone D, Rossano F. STRATEGIE NELLA DIAGNOSI DELLA TOXOPLASMOSI NEL NEONATO: SCREENING SIEROLOGICO E METODOLOGIE. Microbiol Med 2006. [DOI: 10.4081/mm.2006.3186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|